Redução da inflamação sistémica após terapêutica de ressincronização cardíaca: uma nova forma de resposta?

Chronic heart failure (CHF) is the final common pathway for various cardiac pathologies and, despite significant progress in its treatment in recent years, this complex clinical syndrome still has a poor prognosis. Cardiac resynchronization therapy (CRT) is a wellestablished option in the treatment of CHF that results in significant clinical improvements, ventricular reverse remodeling, and lower mortality in selected patients. However, based on current selection criteria, a significant proportion of patients with CHF do not respond positively to CRT. It is therefore important to identify new predictors that will improve the selection of potential responders to this therapy. Although the pathophysiology of CHF is still poorly understood, neurohormonal stimulation and immune activation have been shown to be involved in the development and progression of this systemic disease. There is growing evidence that levels of various pro-inflammatory cytokines are elevated in patients with CHF, and that this inflammatory